Park Avenue Securities LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 31.4% during the ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

The latest trading session saw Gilead Sciences (GILD) ending at $92.96, denoting a +1.22% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of ...

Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy.

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other dividend stocks. Macroeconomic factors have weighed on US stocks in the final ...

Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...